Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials

Ophthalmology
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupB Katz

Abstract

To evaluate the safety of pegaptanib sodium injection, a specific vascular endothelial growth factor (VEGF) antagonist, in the treatment of neovascular age-related macular degeneration (AMD) during 2 years of therapy. Two concurrent, prospective, randomized, multicenter, double-masked, sham-controlled studies. Patients with all angiographic choroidal neovascularization lesion compositions of AMD received either intravitreous pegaptanib sodium (0.3 mg, 1 mg, 3 mg) or sham injections every 6 weeks for 54 weeks. Those initially assigned to pegaptanib were re-randomized (1:1) to continue or discontinue therapy for 48 more weeks; sham-treated patients were re-randomized (1:1:1:1:1) to continue sham, discontinue, or receive one of the pegaptanib doses. All reported adverse events, serious adverse events, and deaths. In year 1, 1190 subjects received at least one study treatment (0.3 mg, n = 295; 1 mg, n = 301; 3 mg, n = 296; sham, n = 298); 7545 intravitreous injections of pegaptanib were administered. In year 2, 425 subjects (0.3 mg, n = 128; 1 mg, n = 126; 3 mg, n = 120; sham, n = 51) continued the same masked treatment as in year 1 and received at least one study treatment in year 2; 2663 intravitreous injections of pegaptanib wer...Continue Reading

References

Nov 1, 1984·Archives of Ophthalmology·F L FerrisL Hyman
Nov 7, 1995·Proceedings of the National Academy of Sciences of the United States of America·L P AielloL E Smith
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz KabbinavarEmily Bergsland
Nov 12, 2003·Archives of Ophthalmology·Neil M BresslerUNKNOWN Age-Related Eye Disease Study Research Group
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonFairooz Kabbinavar
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Oct 20, 2004·Retina·Rama D JagerEmmett T Cunningham
Dec 31, 2004·The New England Journal of Medicine·Evangelos S GragoudasUNKNOWN VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarWilliam F Novotny

❮ Previous
Next ❯

Citations

Oct 30, 2007·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·C H MeyerN Eter
Feb 8, 2008·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·C H MeyerH Heimann
Apr 22, 2008·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Sophie J BakriDarius M Moshfeghi
Jul 22, 2008·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·S Y CohenA Beresniak
Feb 23, 2010·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Benjamin P Nicholson, Andrew P Schachat
Dec 18, 2008·Japanese Journal of Ophthalmology·Sebastian Wolf
Oct 28, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Michael LukasonAbraham Scaria
Dec 2, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Timothy K MaclachlanSamuel Wadsworth
Jan 30, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Shannon E BoyeWilliam W Hauswirth
Sep 29, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jeffrey W-D FoyManju Patel
Mar 4, 2008·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Jena J SteinleVannak C Chin
Oct 25, 2006·International Ophthalmology Clinics·Barrett Katz, Mauro Goldbaum
Jul 11, 2007·Retina·Lawrence A Yannuzzi
Sep 26, 2009·Retina·Jean-Pierre HubschmanSteven D Schwartz
Apr 15, 2008·Current Opinion in Ophthalmology·William E Smiddy
Apr 8, 2009·International Ophthalmology Clinics·Walid Abdallah, Amani A Fawzi
Feb 5, 2011·Pediatric Emergency Care·Savithiri Ratnapalan, Lopamudra Das
Jul 28, 2007·Acta Ophthalmologica Scandinavica·Ursula M Schmidt-ErfurthUNKNOWN European Society for Retina Specialists' Guidelines Committee (EURETINA)
Oct 24, 2006·The British Journal of Ophthalmology·S Michels
May 4, 2007·The British Journal of Ophthalmology·A L TakedaJ Jones
Aug 29, 2007·International Journal of Nanomedicine·David G Birch, Fong Qi Liang
Aug 12, 2009·Clinical Ophthalmology·Jean Pierre HubschmanSteven D Schwartz
Aug 12, 2009·Clinical Ophthalmology·Chiara RosinaGiovanni Staurenghi
Jun 2, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Raymond M SchiffelersGert Storm
Oct 24, 2007·Indian Journal of Ophthalmology·Dhananjay ShuklaEmmett T Cunningham
Jun 11, 2010·Indian Journal of Ophthalmology·Sribhargava NateshB V Priya
Jan 11, 2014·Current Opinion in Ophthalmology·Jeffrey R SooHooMalik Y Kahook
Dec 7, 2013·Mediators of Inflammation·Shivi AgrawalJohn B Christoforidis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.